Fractyl Health (GUTS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Meeting opened with introductions of board members, executive team, independent auditor, and outside counsel.
Agenda and rules of conduct were made available on the virtual meeting webpage.
Stockholders were informed about voting and Q&A procedures.
Board and executive committee updates
Board committee chairs and members were introduced, including Audit, Nominating and Governance, and Compensation and Human Strategy Committees.
Shareholder proposals
Two proposals were presented: election of three Class II directors for a three-year term and ratification of the independent auditor for the next fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Fractyl Health
- A scalable, high-margin procedure addresses the urgent post-GLP-1 weight maintenance gap.GUTS
Status update - Revita offers a scalable, cost-effective solution for post-GLP-1 weight maintenance with rapid path to profitability.GUTS
Corporate presentation - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.GUTS
Proxy filing - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.GUTS
Proxy filing - Revita nears pivotal data for post-GLP-1 weight maintenance as Rejuva enters clinical trials.GUTS
Canaccord Genuity's 46th Annual Growth Conference - Revita maintained up to 84% of GLP-1 weight loss; net loss narrowed, but liquidity risks persist.GUTS
Q2 2026 - Revita enabled up to 84% weight loss retention at one year post-GLP-1, with strong safety data.GUTS
Study result - Innovative device and gene therapy programs target durable weight maintenance in obesity and diabetes.GUTS
Chardan's 8th Annual Genetic Medicines Conference - Q1 2026 net income turned positive on non-cash gains; cash runway into early 2027.GUTS
Q1 2026